Impact of radiotherapy when added to androgen-deprivation therapy for locally advanced prostate cancer: Long-term quality-of-life outcomes from the NCIC CTG PR3/MRC PR07 randomized trial

Journal of Clinical Oncology

Volumn 33, Issue 19, 2015, Pages 2151-2157

  Brundage, Michael D ^a   Sydes, Matthew R ^f   Parulekar, Wendy R ^b   Warde, Padraig ^c   Cowan, Richard ^g   Bezjak, Andrea ^c   Kirkbride, Peter ^h   Parliament, Matthew ^d   Moynihan, Clare ⁱ   Bahary, Jean Paul ^e   Parmar, Mahesh K B ^f   Sanders, Karen ^f   Chen, Bingshu E ^b   Mason, Malcolm D ^j  

^a QUEEN S UNIVERSITY   (Canada)

^b Clinical Trials Group   (Canada)

^c PRINCESS MARGARET HOSPITAL   (Canada)

^d CROSS CANCER INSTITUTE   (Canada)

^e CENTRE HOSPITALIER DE L UNIVERSITÉ DE MONTRÉAL   (Canada)

^f UNIVERSITY COLLEGE LONDON   (United Kingdom)

^g UNIVERSITY OF MANCHESTER   (United Kingdom)

^h CLATTERBRIDGE CENTRE FOR ONCOLOGY   (United Kingdom)

ⁱ INSTITUTE OF CANCER RESEARCH   (United Kingdom)

^j CARDIFF UNIVERSITY SCHOOL OF MEDICINE   (United Kingdom)

more..

Author keywords

[No Author keywords available]

Indexed keywords

GONADORELIN AGONIST; ANTIANDROGEN;

ADULT; ADVANCED CANCER; AGED; ANDROGEN DEPRIVATION THERAPY; ARTICLE; CANCER RADIOTHERAPY; CONTROLLED STUDY; DETERIORATION; DIARRHEA; ENTEROPATHY; ERECTILE DYSFUNCTION; EUROPEAN ORGANISATION FOR RESEARCH AND TREATMENT OF CANCER CORE QUESTIONNAIRE; FATIGUE; FUNCTIONAL ASSESSMENT OF CANCER THERAPY PROSTATE QUESTIONNAIRE; HOT FLUSH; HUMAN; IMPOTENCE; INSOMNIA; LETHARGY; LIBIDO DISORDER; MAJOR CLINICAL STUDY; MALE; ORCHIECTOMY; OVERALL SURVIVAL; PHASE 3 CLINICAL TRIAL; PRIORITY JOURNAL; PROSTATE CANCER; QUALITY OF LIFE; QUESTIONNAIRE; RANDOMIZED CONTROLLED TRIAL; RECTUM HEMORRHAGE; SYMPTOMATOLOGY; TREATMENT OUTCOME; TREATMENT RESPONSE; URINARY TRACT FUNCTION; URINE INCONTINENCE; WELLBEING; CHEMORADIOTHERAPY; CLINICAL TRIAL; COMPARATIVE STUDY; MIDDLE AGED; PROSTATIC NEOPLASMS; SURVIVAL ANALYSIS;

AGED; ANDROGEN ANTAGONISTS; CHEMORADIOTHERAPY; HUMANS; MALE; MIDDLE AGED; PROSTATIC NEOPLASMS; QUALITY OF LIFE; SURVEYS AND QUESTIONNAIRES; SURVIVAL ANALYSIS; TREATMENT OUTCOME;

EID: 84937547598     PISSN: 0732183X     EISSN: 15277755     Source Type: Journal    
DOI: 10.1200/JCO.2014.57.8724     Document Type: Article

References (15)

1. Center MM, Jemal A, Lortet-Tieulent J: International variation in prostate cancer incidence and mortality rates. Eur Urol 61:1079-1092, 2012
2. Canadian Cancer Society, Statistics Canada, Provincial/Territorial Cancer Registries, Public Health Agency of Canada: Canadian Cancer Statistics 2012. https://cancer.ca/∼/media/CCS/Canada%20wide/Files%20List/English%20files%20heading/PDF%20-%20Policy%20-%20Canadian%20Cancer%20Statistics%20-%20English/Canadian%20Cancer%20Statistics%202012%20-%20English.ashx
3. Warde P, Mason M, Ding K, et al: Combined androgen deprivation therapy and radiation therapy for locally advanced prostate cancer: A randomised, phase 3 trial. Lancet 378:2104-2111, 2012
4. Calvert M, Blazeby J, Altman DG, et al: Reporting of patient-reported outcomes in randomized trials: The CONSORT PRO extension. JAMA 309:814-822, 2013
5. Efficace F, Osoba D, Gotay C, et al: Has the quality of health-related quality of life reporting in cancer clinical trials improved over time? Towards bridging the gap with clinical decision making. Ann Oncol 18:775-781, 2007
6. Esper P, Mo F, Chodak G, et al: Measuring quality of life in men with prostate cancer using the functional assessment of cancer therapy-prostate instrument. Urology 50:920-928, 1997
7. Aaronson NK, Ahmedzai S, Bergman B, et al: The European Organisation for Research and Treatment of Cancer QLQ-C30: A quality-of-life instrument for use in international clinical trials in oncology. J Natl Cancer Inst 85:365-376, 1993
8. Osoba D, Rodrigues G, Myles J, et al: Interpreting the significance of changes in health-related quality-of-life scores. J Clin Oncol 16:139-144, 1998
9. Cella D, Nichol MB, Eton D, et al: Estimating clinically meaningful changes for the Functional Assessment of Cancer Therapy-Prostate: Results from a clinical trial of patients with metastatic hormone-refractory prostate cancer. Value Health 12:124-129, 2009
10. Osoba D, Bezjak A, Brundage M, et al: Analysis and interpretation of health-related quality-oflife data from clinical trials: Basic approach of the National Cancer Institute of Canada Clinical Trials Group. Eur J Cancer 41:280-287, 2005
11. Moynihan C: Men, women, gender and cancer. Eur J Cancer Care (Engl) 11:166-172, 2002
12. Moul JW, Dawson N: Quality of life associated with treatment of castration-resistant prostate cancer: A review of the literature. Cancer Invest 30:1-12, 2012
13. Alibhai SM, Breunis H, Timilshina N, et al: Impact of androgen-deprivation therapy on physical function and quality of life in men with nonmetastatic prostate cancer. J Clin Oncol 28:5038-5045, 2010
14. Fransson P, Lund JA, Damber JE, et al: Quality of life in patients with locally advanced prostate cancer given endocrine treatment with or without radiotherapy: 4-year follow-up of SPCG-7/SFUO-3, an open-label, randomised, phase III trial. Lancet Oncol 10:370-380, 2009
15. Denham JW, Steigler A: Picking the optimal duration of hormonal therapy in men with high-risk and locally advanced prostate cancer treated with radiotherapy. Semin Radiat Oncol 23:206-214, 2013